ArticleCancer biology & therapy2011

VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells.

Lymor Ringer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.